Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
(d) On September 9, 2021, the Board of Directors (the "Board") of Syros
Pharmaceuticals, Inc. (the "Company") appointed Deborah Dunsire, M.D., as a
Class II director. Dr. Dunsire was also appointed to the Compensation Committee
and the Research and Development Committee of the Board.
Dr. Dunsire, age 59, has more than 30 years of clinical, commercial, and
international management experience from the biotech and pharmaceutical
industry, primarily in the fields of oncology and CNS. Dr. Dunsire currently
serves as President and Chief Executive Officer of H. Lundbeck A/S, a public
biopharmaceutical company, and has held this position since September 2018. She
previously served as President and Chief Executive Officer and a Director of
Xtuit Pharmaceuticals, Inc., a private biopharmaceutical company, from January
2017 to March 2018. Prior to her position at Xtuit, she served as President and
Chief Executive Officer and a Director of FORUM Pharmaceuticals Inc., a private
pharmaceutical company, from July 2013 to May 2016. Prior to FORUM, Dr. Dunsire
worked for Takeda Pharmaceutical Company Limited as a corporate officer from
June 2010 to June 2011 and a Director from June 2011 to June 2013. She served as
President, Chief Executive Officer and a Director of Millennium Pharmaceuticals,
Inc. between 2005 and 2008, when it was acquired by Takeda, and then as
President and Chief Executive Officer of Millennium: The Takeda Oncology Company
after the acquisition between 2008 and 2013. Prior to Millennium, Dr. Dunsire
held various roles of increasing responsibility at Novartis Pharma AG between
1988 and 2005. She currently serves as a Board member of Ultragenyx
Pharmaceutical Inc, a public biopharmaceutical company. She obtained an MBBCh
from the University of the Witwatersrand in South Africa. We believe that
Dr. Dunsire is qualified to serve on the Board due to her extensive experience
in the biotechnology and pharmaceutical sectors, including service as the chief
executive officer of various pharmaceutical companies.
Pursuant to the Company's director compensation program, Dr. Dunsire will be
entitled to an annual cash retainer of $40,000 per year for service on the
Board. Dr. Dunsire is also entitled to an annual retainer of $5,000 for service
as a member of each of the Compensation Committee and the Research and
Development Committee of the Board. These fees will be payable in arrears in
equal quarterly installments on the last day of each calendar quarter, provided
that the amount of such payments will be prorated for any portion of a quarter
in which Dr. Dunsire has not served as a director or on a committee, as
applicable. We will also reimburse Dr. Dunsire for reasonable travel and
out-of-pocket expenses incurred in connection with attending meetings of our
Board and its committees.
In addition, upon her appointment to the Board, Dr. Dunsire was granted an
option to purchase 35,000 shares of the Company's common stock, with an exercise
price equivalent to the closing price of a share of the Company's common stock
as reported by Nasdaq on the date of grant, which option will vest as to 16.66%
of the shares on the six month anniversary of the date of grant and as to the
remainder of the shares monthly thereafter until the third anniversary of the
date of grant, subject to continued service, with full acceleration upon a
change-in-control of the Company. Immediately following each annual meeting of
our stockholders occurring after Dr. Dunsire has completed six months of service
on the Board, she will be granted an option to purchase 17,500 shares of the
Company's common stock, with an exercise price equivalent to the closing price
of a share of the Company's common stock as reported by Nasdaq on the date of
grant, which option will vest as to 50% of the shares on the six month
anniversary of the date of grant and as to the remainder of the shares monthly
thereafter until the first anniversary of the date of grant, subject to
continued service, with full acceleration upon a change-in-control of the
Company.
Our certificate of incorporation provides for the Company to indemnify its
directors and executive officers to the fullest extent permitted by Delaware
law. On September 9, 2021, we entered into an indemnification agreement with
Dr. Dunsire on terms identical to those entered into with the Company's other
directors and executive officers. This indemnification agreement requires the
Company, among other things, to advance expenses, including attorneys' fees, to
our directors and executive officers in connection with an indemnification
claim, subject to very limited exceptions.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
10.1 Form of Director and Officer Indemnification Agreement by and
between the Registrant and each of the directors of the
Registrant. Previously filed on June 3, 2016 as Exhibit 10.12 to
the Registrant's Registration Statement on Form S-1 (SEC File
Number 333-211818) and incorporated herein by reference.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
SYROS PHARMACEUTICALS, INC. 
